Comparing Rapport Therapeutics (NASDAQ:RAPP) and Compass Therapeutics (NASDAQ:CMPX)

Compass Therapeutics (NASDAQ:CMPX) and Rapport Therapeutics (NASDAQ:RAPP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Volatility and Risk

Compass Therapeutics has a beta of 1.48, indicating that its stock price is 48% more volatile than the S&P 500. Comparatively, Rapport Therapeutics has a beta of 1.51, indicating that its stock price is 51% more volatile than the S&P 500.

Valuation & Earnings

This table compares Compass Therapeutics and Rapport Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Therapeutics	$850,000.00	1,129.27	-$66.49 million	($0.43)	-12.40
Rapport Therapeutics	N/A	N/A	-$111.48 million	($2.86)	-10.14

Compass Therapeutics has higher revenue and earnings than Rapport Therapeutics. Compass Therapeutics is trading at a lower price-to-earnings ratio than Rapport Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and target prices for Compass Therapeutics and Rapport Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Therapeutics	1	0	13	1	2.93
Rapport Therapeutics	1	0	7	1	2.89

Compass Therapeutics currently has a consensus price target of $13.00, indicating a potential upside of 143.90%. Rapport Therapeutics has a consensus price target of $51.40, indicating a potential upside of 77.24%. Given Compass Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Compass Therapeutics is more favorable than Rapport Therapeutics.

Profitability

This table compares Compass Therapeutics and Rapport Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Compass Therapeutics	N/A	-43.61%	-38.05%
Rapport Therapeutics	N/A	-28.85%	-27.27%

Insider & Institutional Ownership

68.4% of Compass Therapeutics shares are held by institutional investors. 29.8% of Compass Therapeutics shares are held by company insiders. Comparatively, 13.6% of Rapport Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Compass Therapeutics beats Rapport Therapeutics on 8 of the 12 factors compared between the two stocks.

About Compass Therapeutics

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

About Rapport Therapeutics

Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.